The changing therapeutic landscape for urticaria, angioedema, and anaphylaxis is evidenced by emerging treatments reported at ...
US-based biopharmaceutical company KalVista Pharmaceuticals has finished enrolling subjects in its KONFIDENT-KID trial of ...
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
The following is a summary of “Comorbidities in Canadian patients with hereditary angioedema: a quantitative survey study,” ...
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID ...
Pharmaceuticals announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of sebetralstat, an ...
Opinion
4hOpinion
Rare Disorders NZ has fought for 300,000 Kiwis living with rare conditions, a group long overlooked by our healthcare system. As we reflect on our anniversary and th ...
Analysts at William Blair issued their Q1 2026 earnings estimates for shares of Intellia Therapeutics in a research report issued on Wednesday, March 26th. William Blair analyst M. Minter anticipates ...
The following is a summary of “Patient and physician perspectives on disease burden in chronic spontaneous urticaria,” ...
Multiple sclerosis turned Hollie Amadio's life upside-down, but a chance encounter gave her a new purpose on behalf of the MS ...
Following Winstrol treatment, a noticeable decline in levels of Hormone Binding Globulin (SHBG) has been noted. This effect ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback